Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes
Year: 2013
Type: article
Abstract: GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic β-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.
Source: ACS Medicinal Chemistry Letters
DOI: 10.1021/ml400186z
Authors: Narihiro Toda, Xiaolin Hao, Yasuyuki Ogawa, Kozo Oda, Ming Yu, Zice Fu, Yi Chen, Yongjae Kim, Mike Lizarzaburu, Sarah Lively, Shauna Lawlis, Michiko Murakoshi, Futoshi Nara, Nobuaki Watanabe, Jeff D. Reagan, Hui Tian, Angela Fu, Alykhan Motani, Qingxiang Liu, Yi-Jyun Lin, Run Zhuang, Yumei Xiong, Peter Fan, Julio Medina, Leping Li, Masanori Izumi, Ryo Okuyama, Satoshi Shibuya
Institutions: Daiichi-Sankyo (Japan), Amgen (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1984003917
